• Badros, A., Weikel, D., Salama, A., Goloubeva, O., Schneider, A., Rapoport, A., Fenton, R., Gahres, N., Sausville, E., Ord, R. & Meiller, T. (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Journal of Clinical Oncology, 24, 945952.
  • Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L.A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., Terpos, E. & Dimopoulos, M.A. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology, 23, 85808587.
  • Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., Blacklock, H., Bell, R., Simeone, J.F., Reitsma, D.J., Heffernan, M., Seaman, J. & Knight, R.D. (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal of Clinical Oncology, 16, 593602.
  • Berenson, J.R., Hillner, B.E., Kyle, R.A., Anderson, K., Lipton, A., Yee, G.C. & Biermann, J.S. (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology, 20, 37193736.
  • Durie, B.G., Katz, M. & Crowley, J. (2005a) Osteonecrosis of the jaw and bisphosphonates. New England Journal of Medicine, 353, 99100 [letter].
  • Durie, B.G.M., Katz, M., McCoy, J. & Crowley, J. (2005b) Osteonecrosis of the jaws in myeloma: analysis of risk factors including time dependency of Aredia and Zometa use, steroid use and underlying dental problems. Haematologica, 90, 190 [abstract].
  • McGregor, A.D. & MacDonald, D.G. (1989) Age changes in the human inferior alveolar artery: a histological study. British Journal of Oral and Maxillofacial Surgery, 27, 371374.
  • Ruggiero, S., Gralow, J., Marx, R.E., Hoff, A.O., Schubert, M.M., Huryn, J.M., Toth, B., Damato, K. & Valero, V. (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice, 2, 714.
  • Santini, D., Vincenzi, B., Dicuonzo, G., Avvisati, G., Massacesi, C., Battistoni, F., Gavasci, M., Rocci, L., Tirindelli, M.C., Altomare, V., Tocchini, M., Bonsignori, M. & Tonini, G. (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clinical Cancer Research, 9, 28932897.
  • Shankland, W.E. (2003) Medullary and odontogenic disease in the painful jaw: clinicopathological review of 500 cases. Cranio, 20, 295303.
  • Smith, A., Wisloff, F. & Samson, D. (2006) Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal of Haematology, 132, 410451.
  • Terpos, E. & Rahemtulla, A. (2004) Bisphosphonate treatment for multiple myeloma. Drugs of Today, 40, 2940.